Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zhuang, Xiufen ^a   Zhang, Wen ^a   Chen, Yatong ^b   Han, Xiangping ^c,d   Li, Jie ^a   Zhang, Yu ^a   Zhang, Youhui ^a   Zhang, Shuren ^a   Liu, Binlei ^a,c,d  

^a CANCER HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

^d Tianjin International Joint Academy of Biotechnology and Medicine   (China)

Author keywords

ALDH; Breast cancer; Cancer stem cells; Chemoresistant; Doxorubicin; Herpes simplex virus; Oncolytic virus

Indexed keywords

ALDEHYDE DEHYDROGENASE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ASSAY; FEMALE; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; SURVIVAL RATE; SYSTEMIC THERAPY; WESTERN BLOTTING;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84869868723     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-549     Document Type: Article

References (74)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010, 5(11):e13943. 10.1371/journal.pone.0013943, 2978678, 21085683.
3. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284. 10.1146/annurev.med.58.062105.204854, 17002552.
4. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, 2nd Van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69(5):1951-1957. 10.1158/0008-5472.CAN-08-2023, 3198868, 19244128.
5. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006, 355(12):1253-1261. 10.1056/NEJMra061808, 16990388.
6. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284. 10.1038/nrc1590, 15803154.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760. 10.1038/nature05236, 17051156.
8. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005, 102(19):6942-6947. 10.1073/pnas.0502320102, 1087514, 15860580.
9. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004, 101(39):14228-14233. 10.1073/pnas.0400067101, 521140, 15381773.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401. 10.1038/nature03128, 15549107.
12. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8):3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
13. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7(3):330-338. 10.1158/1541-7786.MCR-08-0393, 19276181.
14. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
15. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V, Bruckner T, Zoeller M, Ho AD. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009, 37(12):1423-1434. 10.1016/j.exphem.2009.10.001, 19819294.
16. Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW, Huang EH. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 2009, 69(20):8208-8215. 10.1158/0008-5472.CAN-09-1132, 2776663, 19808966.
17. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010, 70(12):5163-5173. 10.1158/0008-5472.CAN-09-3806, 20516116.
18. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32(9):1195-1201. 10.1002/hed.21315, 2991066, 20073073.
19. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immuno 2001, 20:20-21.
20. Matilainen H, Yu XW, Tang CW, Berridge MV, McConnell MJ. Sphere formation reverses the metastatic and cancer stem cell phenotype of the murine mammary tumour 4T1, independently of the putative cancer stem cell marker Sca-1. Cancer Lett 2012, 323(1):20-28. 10.1016/j.canlet.2012.03.028, 22459350.
21. Park SJ, Kim RJ, Nam JS. Inhibitor of DNA-binding 4 contributes to the maintenance and expansion of cancer stem cells in 4T1 mouse mammary cancer cell line. Laboratory animal research 2011, 27(4):333-338. 10.5625/lar.2011.27.4.333, 3251764, 22232642.
22. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009, 4(1):e4235. 10.1371/journal.pone.0004235, 2626279, 19156211.
23. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009, 17(10):1677-1682. 10.1038/mt.2009.193, 2835002, 19672244.
24. Liu TC, Kirn D. Targeting the untargetable: oncolytic virotherapy for the cancer stem cell. Mol Ther 2007, 15(12):2060-2061. 10.1038/sj.mt.6300337, 18026182.
25. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5(12):965-976. 10.1038/nrc1750, 16294217.
26. Sugiura S, Goshima F, Takakuwa H, Sata T, Nakashima T, Nishiyama Y. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses. Otolaryngol Head Neck Surg 2004, 130(4):470-478. 10.1016/j.otohns.2004.01.001, 15100647.
27. Israyelyan A, Chouljenko VN, Baghian A, David AT, Kearney MT, Kousoulas KG. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J 2008, 5:68. 10.1186/1743-422X-5-68, 2453120, 18518998.
28. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr 2008, 2(3):208-213. 10.4161/cam.2.3.6353, 2634086, 19262110.
29. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001, 98(11):6396-6401. 10.1073/pnas.101136398, 33479, 11353831.
30. Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009, 69(8):3472-3481. 10.1158/0008-5472.CAN-08-3886, 2785462, 19351838.
31. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000, 6(8):3342-3353.
32. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999, 1(2):162-169. 10.1038/sj.neo.7900016, 1508135, 10933051.
33. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M, Gungor D, Suehnel J, Moebius U, Lechmann M. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006, 17(12):1241-1253. 10.1089/hum.2006.17.1241, 17117895.
34. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006, 98(1):38-50. 10.1093/jnci/djj003, 16391370.
35. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995, 145:167-177. 10.1111/j.1600-065X.1995.tb00081.x, 7590825.
36. Martin S, Zhu XX, Silverstein SJ, Courtney RJ, Yao F, Jenkins FJ, Rouse BT. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0. J Gen Virol 1990, 71(Pt 10):2391-2399.
37. Osorio Y, Cai S, Ghiasi H. Treatment of mice with anti-CD86 mAb reduces CD8+ T cell-mediated CTL activity and enhances ocular viral replication in HSV-1-infected mice. Ocul Immunol Inflamm 2005, 13(2-3):159-167.
38. Tribble ND, Burka JF, Kibenge FS, Wright GM. Identification and localization of a putative ATP-binding cassette transporter in sea lice (Lepeophtheirus salmonis) and host Atlantic salmon (Salmo salar). Parasitology 2008, 135(2):243-255.
39. Godoy-Ramirez K, Makitalo B, Thorstensson R, Sandstrom E, Biberfeld G, Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 2005, 68(2):71-80.
40. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10(4):292-303. 10.1038/sj.gt.3301885, 12595888.
41. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008, 18(3):370-377. 10.1111/j.1750-3639.2008.00130.x, 18371181.
42. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3(8):e3077. 10.1371/journal.pone.0003077, 2518121, 18728788.
43. Kim RJ, Kim SR, Roh KJ, Park SB, Park JR, Kang KS, Kong G, Tang B, Yang YA, Kohn EA, et al. Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett 2010, 287(2):172-181. 10.1016/j.canlet.2009.06.010, 19586713.
44. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344. 10.1158/0008-5472.CAN-06-3126, 16990346.
45. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12(2):374-390. 10.1111/j.1582-4934.2007.00211.x, 18182063.
46. Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, Dash S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 2011, 178(2):838-852. 10.1016/j.ajpath.2010.10.029, 3069823, 21281816.
47. Dean M. Cancer stem cells: Implications for cancer causation and therapy resistance. Discov Med 2005, 5(27):278-282.
48. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26(17):2813-2820. 10.1200/JCO.2008.16.3931, 2789399, 18539959.
49. Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 2008, 10(4):210-223. 10.1186/bcr2111, 2575525, 18671830.
50. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229. 10.1124/pr.56.2.6, 15169927.
51. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992, 44(Suppl 4):17-28. discussion 66-19..
52. Chen JH, Ling R, Yao Q, Li Y, Chen T, Wang Z, Li KZ. Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer 2005, 12(1):93-100. 10.1677/erc.1.00871, 15788641.
53. Molyneux G, Andrews M, Sones W, York M, Barnett A, Quirk E, Yeung W, Turton J. Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol Toxicol 2011, 27(1):13-40. 10.1007/s10565-010-9167-1, 20589437.
54. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97(11):2869-2879. 10.1002/cncr.11407, 12767102.
55. Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, Reisfeld RA. Characterization of stem cell-like cancer cells in immune-competent mice. Blood 2006, 108(12):3906-3912. 10.1182/blood-2006-05-024687, 16912222.
56. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5(4):e10365. 10.1371/journal.pone.0010365, 2860989, 20442777.
57. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010, 17(3):718-730. 10.1245/s10434-009-0809-6, 19915919.
58. Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, Yancey Gillespie G. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol 2009, 95(2):199-209. 10.1007/s11060-009-9926-0, 19521665.
59. Li H, Dutuor A, Fu X, Zhang X. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 2007, 9(3):161-169. 10.1002/jgm.1005, 17266169.
60. Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004, 9(5):658-665. 10.1016/j.ymthe.2004.02.019, 15120326.
61. Loudon PT, McLean CS, Martin G, Curry J, Leigh Shaw M, Hoogstraten C, Verdegaal E, Osanto S. Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma. J Gene Med 2003, 5(5):407-416.
62. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8(1):59-73. 10.1038/nri2216, 18097448.
63. Bagalkot V, Lee IH, Yu MK, Lee E, Park S, Lee JH, Jon S. A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex. Mol Pharm 2009, 6(3):1019-1028. 10.1021/mp800177f, 19338265.
64. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28(45):3949-3959. 10.1038/onc.2009.252, 19718046.
65. Israyelyan A, Shannon EJ, Baghian A, Kearney MT, Kousoulas KG. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother Pharmacol 2009, 64(6):1201-1210. 10.1007/s00280-009-0987-8, 19308409.
66. Walker JD, Sehgal I, Kousoulas KG. Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol 2011, 85(14):7363-7371. 10.1128/JVI.00098-11, 3126558, 21543507.
67. Yun CO. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 2008, 10(4):356-361.
68. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets 2007, 7(2):149-155. 10.2174/156800907780058907, 17346106.
69. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 2006, 103(34):12873-12878. 10.1073/pnas.0605496103, 1568940, 16908838.
70. Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?. Future Oncol 2010, 6(4):619-634. 10.2217/fon.10.18, 2904234, 20373873.
71. Ribacka C, Hemminki A. Virotherapy as an approach against cancer stem cells. Curr Gene Ther 2008, 8(2):88-96. 10.2174/156652308784049372, 18393830.
72. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999, 10(18):3013-3029. 10.1089/10430349950016410, 10609661.
73. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006, 12(22):6737-6747. 10.1158/1078-0432.CCR-06-0759, 17121894.
74. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008, 10(4):371-379.